PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known 10/086,145 **Application Number** Filing Date October 19, 2001 **First Named Inventor** Pairet, M. et al 1614 Art Unit To be Assigned **Examiner Name** Attorney Docket Number 1/1174

Sheet 1 of

			U.S. PATE	ENT DOCUMENTS		1
Examiner		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	1
Initials'	No.1	Number - Kind Code ² (if known	MM-DD-YYYY	Applicant of ched bocoment	Figures Appear]
		US-				
		US-		•	-11/5	G
	1	US-			PECEIVE JUN 2 1 21 TECH CENTER	-
	[US-			HEU-	
		US-			1 21	u3
		US-			11N 21	(,,,
		US-			301.	0000
		US-				180015200
		US-			- OU CENTER	1000
		US-			TECH OF "	!
		US-			,	
		US-				
j		U\$-				l
		.us-			OOTIV OF	DARERE
		uş-			COPY OF	
		US-			ORIGINAL	LY FILED
		US-				
		US-				
		US-				
		lus-				

_		_ FOR	EIGN PATENT D	OCUMENTS	
Examiner Initials	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁶
And the state of		EP0504 0112 A2 DE 198 35 346 A1	05/03/1992 05/08/1998	Ciba-Geigy AG Boetninger Ingelhelm Pharma KG	No translation nor been provided.

Examiner Date Signature Considered

Engish language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Coi	mplete if Known	250	EIVED
Application Number	10/086,145	REU	FIACO
Filing Date	October 19, 2001		
First Named Inventor	Pairet, M. et al		1 2002
Group Art Unit	1614	JUN S	1 2002
Examiner Name	To be Assianed		
Attorney Docket Number	1/1174	TEOU CEM	TER 1600/29(
		TECHNOLIN	I TIT TOOGLES

		OTHER ROLOR AND MON PATENT LITERATURE CONTINENTS	_
	1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
Examiner nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
Mo		F. MON, et al; Aerosol Therapy in Asthma, Revue Des Maladies Respiratoires, Bd. 6, Nr. 3, 1989 Seiten 189-200 - XP001078722	
		G. BLAZANO, et al, Effectiveness and Acceptability of a Domicilialry Multidrug Inhalation Treatment in Elderly Patients with Chronic Airflow Obstruction: Metered Dose Inhaler Versus Jet Nebulilzer. Journal of Aerosol Medicine, Vol. 13, No. 1, 2000, PP 25-33	-
		RUTGERS, STEVEN R., et al; Short-term Treatment with Budesonide Does Not Improve Hyperresponsiveness to Adenosine 5- Monophosphate in COPD,	
		American Journal of Respiratory and Critical Care Medicine, Vol. 157, pp 880-887	
		CONSTANT P. van SCHAYCK, et al; Periodic Treatment Regimens with Inhaled Steroids in Asthma or Chronic Obstructive Pulmonary Disease,	
		Journal of American Medical Association, July 12, 1995, Vol. 274, No. 2, pp 161-164	
		DEMETRI PAVIA, et al; Preliminary Data from Phase II Studies wtih Respimat, a Propellant-Free Soft Mist Inhaler, Journal of Aerosol Medicine, Vol. 12, Supplement 1, 1999 pp S-33-S-39 KOICHI NISHIMURA, et al; Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic	
(VB		asthma, Allergology International (1999) 48: 85-88, Short Communication XP-001070756	
P.	٠,	COPY OF PAPERS ORIGINALLY FILED	

Examiner Date 11/15/ Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.